Portfoliotracker

Cellectis S.A.

ALCLS.PA · PARIS · Healthcare Biotechnology 0/100 E

1,013 €
▲ +0,013 (+1,30 %)
Closed delayed by 15 min
Price as of 17. 11. 17:35, fetched 17. 11. 19:24
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap101 mil. € P/E– Forward P/E-0,6 P/S3,1 P/B2,0 EV/EBITDA0,2 Dividend yield– FCF yield– EPS-0,55 € Net margin0,0 % Return on equity-307,5 % Beta– Debt / equity–
52-week range 0,90 to 4,75
3-month average volume0,5 M

We do not have financial statements yet

The company reports in USD, while the price is quoted in EUR. We do not convert statements between currencies yet, because the multiples (P/E, P/S and others) would come out wrong, so we do not show them here. You can see the price and its history above.

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Employees
224
Country
France
Data since
7. 2. 2007

Explore further

Similar companies GNFT.PAIPH.PANANO.PAADOC.PADBV.PA

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account